Placebo matching dupilumab

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Allergic RhinitisPeanut Allergy

Phase 2

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

CompletedNCT03558997

Regeneron PharmaceuticalsAllergic Rhinitis

Start: 2018-06-07End: 2019-06-13Updated: 2020-05-28

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

CompletedNCT03682770

Regeneron PharmaceuticalsPeanut Allergy

Start: 2018-10-03End: 2021-07-23Updated: 2024-02-07

Related Papers

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy

Allergy2024-12-1425 citations

Anaphylactic reaction requiring epinephrine in a <scp>10‐year‐old</scp> patient undergoing peanut challenge while on dupilumab therapy

Pediatric Allergy and Immunology2024-02-011 citations

Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis

The Journal of Clinical Pharmacology2021-11-188 citations

Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial

Journal of Asthma and Allergy2021-08-0159 citations

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

JAMA Dermatology2019-11-06479 citations